Clinical trials: Postmenopausal Female Patients
- Condition Postmenopausal Female Patients
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Osteoporosis, Postmenopausal
Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis
This is a randomized open label, multi-centre study for Korean women with postmenopausal osteoporosis, evaluating the preference for either the once-monthly dosing of ibandronate or the once-weekly dosing of risedronate.
- Trial name
- NCT00405392
- Testing
- Ibandronate (SB743830HD)
- Volunteers
- 365 people
- Sponsor
- GlaxoSmithKline
Postmenopausal Osteoporosis
Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis
The main objective of this observational study was to describe medication-taking behavior of patients treated with denosumab for postmenopausal osteoporosis (PMO) at 12 and 24 months.
- Trial name
- NCT01668589
- Where
- 144 sites in Austria, Belgium and 2 more
- Volunteers
- 1,501 people
- Sponsor
- Amgen
Post Menopausal Osteoporosis
A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis
This study will evaluate whether an early positive response to once-monthly oral ibandronate in treatment-naive participants with postmenopausal osteoporosis is predictive of efficacy later in treatment.
- Trial name
- NCT02598934
- Testing
- Ibandronate
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 308 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer
Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer
Long term efficacy of exemestane as compared to megestrol acetate in the treatment of women with natural or induced postmenopausal status with advanced breast cancer whose disease has progressed following anti-estrogens or…
- Trial name
- NCT01237327
- Testing
- Megestrol acetate, exemestane (Aromasin)
- Where
- 7 sites in China
- Volunteers
- 84 people
- Sponsor
- Pfizer
Breast Cancer
Arimidex Therapy Compliance Electronic Monitoring System
ARTEMIS is a study to assess how educational material affects overall adherence to anastrozole by evaluation of patients' electronically compiled dosing histories.
- Trial name
- ARTEMIS (NCT00936442)
- Testing
- Anastrozole, Educational materials
- Where
- 4 sites in Belgium
- Volunteers
- 104 people
- Sponsor
- AstraZeneca
Postmenopausal Osteoporosis
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
This study will evaluate participant-reported preference for either ibandronate or a comparator drug in women with postmenopausal osteoporosis.
- Trial name
- NCT02598440
- Testing
- Alendronate, Ibandronate
- Where
- 54 sites in United States
- Volunteers
- 341 people
- Sponsor
- Hoffmann-La Roche
Post-Menopausal Osteoporosis
BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
This single arm study will assess participant preference for monthly Bonviva, versus daily or weekly alendronate or risedronate, in the treatment of postmenopausal osteoporosis.
- Trial name
- NCT00545779
- Testing
- Ibandronate
- Where
- 32 sites in Albania, Bosnia and Herzegovina and 4 more
- Volunteers
- 677 people
- Sponsor
- Hoffmann-La Roche
Postmenopausal Women Osteoporosis
Post-menopausal Women Osteoporosis(Phase III)
The purpose of this study is to evaluate the efficacy and the safety of Risedronate, cholecalciferol combination tablet in patients with Osteoporosis
- Trial name
- NCT01806792
- Testing
- risedronate combine, Risedronate
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Breast Neoplasms
3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer
The study assesses the effect of a further 3 years adjuvant treatment with anastrozole vs. an untreated control group after initial 5 years of adjuvant hormone-therapy.
- Trial name
- NCT00300508
- Testing
- Anastrozole
- Where
- 51 sites in Austria
- Volunteers
- 856 people
- Sponsor
- AstraZeneca
Postmenopausal Osteoporosis
Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.
Dose-response in Japanese patients with postmenopausal osteoporosis.
- Trial name
- NCT00238745
- Testing
- Bazedoxifene
- Volunteers
- 375 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Rheumatoid Arthritis
A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate
The objective of this study is to evaluate the efficacy, pharmacokinetics, pharmacodynamics and safety of ASP1707 in combination with MTX in postmenopausal female patients with RA.
- Trial name
- NCT02884635
- Testing
- ASP1707, Methotrexate
- Where
- 27 sites in Japan
- Volunteers
- 72 people
- Sponsor
- Astellas Pharma Inc
Postmenopausal Osteoporosis
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
This study will investigate participant satisfaction (including compliance, preference, tolerability) with once-monthly Bonviva in women with post-menopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or…
- Trial name
- NCT02604836
- Testing
- Ibandronate
- Where
- 142 sites in United States
- Volunteers
- 1,711 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
An Observational Study of Adherence to Anastrozole in Early Breast Cancer Treatment
The purpose of this study is to describe adherence to anastrozole treatment current practice: cases where anastrozole treatment was halted ( timescale and causes) and estimate the proportion of postmenopausal women with early…
- Trial name
- NCT00737009
- Where
- 3 sites in Vietnam
- Volunteers
- 259 people
- Sponsor
- AstraZeneca
Postmenopausal Osteoporosis
A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
This single arm study will assess the efficacy and safety of quarterly intravenous Bonviva in women with post-menopausal osteoporosis. All patients will receive Bonviva 3mg i.v. every 3 months.
- Trial name
- NCT00493532
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 14 sites in Taiwan
- Sponsor
- Hoffmann-La Roche
Post Menopausal Osteoporosis
ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
This single arm study will continue drug safety surveillance, and assessment of adherence, in patients with postmenopausal osteoporosis who have received monthly oral Bonviva in ML19930, the BonAdAsia study.
- Trial name
- NCT00545090
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 17 sites in Hong Kong, Indonesia and 3 more
- Volunteers
- 561 people
- Sponsor
- Hoffmann-La Roche